Antibodies

Sino Biological Inc.

Experimental mAb subdues type 1 diabetes in laboratory mice

23 February 2021 | By Victoria Rees (Drug Target Review)

A monoclonal antibody given to mice reversed type 1 diabetes by suppressing the actions of glucagon, a study has shown.

Advancing neutralising antibody therapies for COVID-19

17 February 2021 | By Hannah Balfour (Drug Target Review)

In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.

SARS-CoV-2 and immunology: antibody developments

15 February 2021 | By Victoria Rees (Drug Target Review)

Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.

ebook: Vaccines in the digital age

11 February 2021 | By IDBS

In this ebook, we’ll see how digitally enabling your organisation can increase capacity and improve vaccine production.

Novel DNA-based COVID-19 vaccines induce immune responses in mice

5 February 2021 | By Hannah Balfour (Drug Target Review)

The DREP-S vaccine candidate was found to be the most potent of the two investigational vaccine prototypes, eliciting high titers of SARS-CoV-2 neutralising antibodies after a single dose.

New COVID-19 vaccine elicits strong protective immunity in mice and monkeys

5 February 2021 | By Victoria Rees (Drug Target Review)

A new MVA-based vaccine has shown success at inducing COVID-19 antibody and T-cell responses in pre-clinical studies.

COVID-19 vaccine candidate stimulates neutralising antibody production in vivo

3 February 2021 | By Hannah Balfour (Drug Target Review)

The novel haptenised SARS-CoV-2 s-Spike vaccine, BVX-0320, stimulated mice to create neutralising antibodies that were able to reduce SARS-CoV-2 plaques in a neutralisation test.

Majority retain COVID-19 antibodies for six months after infection

3 February 2021 | By Victoria Rees (Drug Target Review)

A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.

N439K variant of SARS-CoV-2 is resistant to some neutralising antibodies, shows study

1 February 2021 | By Hannah Balfour (Drug Target Review)

The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.

Altering balance of fibroblasts could prevent spread of colorectal cancer

1 February 2021 | By Victoria Rees (Drug Target Review)

Researchers have found that colorectal cancer-associated fibroblasts can be altered using a gremlin 1-neutralising antibody or by overexpressing meflin.

Whitepaper: Why BioPharma Lifecycle Management?

28 January 2021 | By IDBS

In this whitepaper we explore some of the major bottlenecks in the development lifecycle and the current barriers to effective digital transformation.

Application note: Automated Simple Westerns in targeted protein degradation

27 January 2021 | By Bio-Techne

Learn how Simple Western automated immunoassays screen degraders and IMiD compounds to quantify degradation activity, providing accurate DC50 and Dmax values.

Novel antibody candidate could offer pan-coronavirus protection

26 January 2021 | By Hannah Balfour (Drug Target Review)

The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.

NSAIDs could be damaging to COVID-19 patients, dependent on timing, suggests study

25 January 2021 | By Hannah Balfour (Drug Target Review)

In murine models of COVID-19, researchers found that non-steroidal anti-inflammatory drugs (NSAIDs) can suppress the inflammatory response and production of antibodies.